A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled “Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells.”
Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items. – Biotech Investments
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Forecast Eckert & Ziegler again achieves sales growth compared to the previous year and confirms
July 22, 2023